Safety Evaluation Study for Patients With Polycythemia Vera

• Status: Recruiting
• Trial end date: 2023-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is PhaseI Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of PPMX-T003 in Polycythemia Vera

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Perseus Proteomics Inc.

Criteria

Inclusion Criteria:

• Confirmed diagnosis of PV according to either the 2008 or 2016 WHO classification criteria

• PV patients being only treated with phlebotomy and the interval is 4-9 weeks

Exclusion Criteria:

• Patients administrated drugs for PV treatment such as hydroxyurea or ruxolitinib (aspirin is excluded)